Exercise enhances the maintenance of smoking cessation in women / Bess H. Marcus (1995)

Public Titre : Exercise enhances the maintenance of smoking cessation in women Type de document : texte imprimé Auteurs : Bess H. Marcus, Auteur ; Anna E. Albrecht, Auteur ; Raymond S. Niaura, Auteur Editeur : Paris [France] : Elsevier Année de publication : 1995 Collection : Addictive Behaviours num. 20 (1) Importance : p.87-92 Catégories : [DIVERS] personne:par sexe:femme [TABAC] sevrage tabagique [TABAC] tabagisme:risque:facteur associé:sport Index. décimale : TA 6.7 Facteurs influents (grossesse, adolescence…) Résumé : Les femmes qui font de l'exercice restent non-fumeuses plus longtemps. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=1423

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 002119	TA 6.7 MAR E	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Longitudinal association between e-cigarette use and respiratory symptoms among US adults: / Emma Karey (2024)  

Public Titre : Longitudinal association between e-cigarette use and respiratory symptoms among US adults: : findings from the population assessment of tobacco and health study waves 4–5 Type de document : document électronique Auteurs : Emma Karey, Auteur ; Shu Xu, Auteur ; Raymond S. Niaura, Auteur Editeur : Public Library of Science (PLOS) Année de publication : 2024 Collection : PLOS ONE, ISSN 1932-6203 Importance : 11 p. Présentation : tab. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Amérique:Amérique du Nord:Etats-Unis [DIVERS] personne:par âge:adulte [TABAC] CANDIDATS:e-cigarette [TABAC] tabagisme:pathologie:pathologie respiratoire:trouble respiratoire Index. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Background We assessed longitudinal effects of e-cigarette use on respiratory symptoms in a nationally representative sample of US adults by combustible tobacco smoking status. Methods We analyzed Waves 4–5 public-use data from the Population Assessment of Tobacco and Health Study. Study sample included adult respondents who reported no diagnosis of respiratory diseases at Wave 4, and completed Waves 4–5 surveys with no missing data on analytic variables (N = 15,291). Outcome was a validated index of functionally important respiratory symptoms based on 7 wheezing/cough questions (range 0–9). An index score of �2 was defined as having important respiratory symptoms. Weighted lagged logistic regression models were performed to examine the association between e-cigarette use status at Wave 4 (former/current vs. never use) and important respiratory symptoms at Wave 5 by combustible tobacco smoking status (i.e., never/former/current smokers), adjusting for Wave 4 respiratory symptom index, sociodemographic characteristics, secondhand smoke exposure, body mass index, and chronic disease. Results Among current combustible tobacco smokers, e-cigarette use was associated with increased odds of reporting important respiratory symptoms (former e-cigarette use: adjusted odds ratio [AOR] = 1.39, 95% confidence interval [CI]: 1.07–1.81; current e-cigarette use: AOR = 1.55, 95% CI: 1.17–2.06). Among former combustible tobacco smokers, former e-cigarette use (AOR = 1.51, 95% CI: 1.06–2.15)—but not current e-cigarette use (AOR = 1.59, 95% CI: 0.91–2.78)—was associated with increased odds of important respiratory symptoms. Among never combustible tobacco smokers, no significant association was detected between e-cigarette use and important respiratory symptoms (former ecigarette use: AOR = 1.62, 95% CI: 0.76–3.46; current e-cigarette use: AOR = 0.82, 95% CI: 0.27–2.56). En ligne : https://doi.org/10.1371/journal.pone.0299834 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10305

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation / J. Taylor Hays (2001)  

Public Titre : Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation Type de document : texte imprimé Auteurs : J. Taylor Hays, Auteur ; Richard D. Hurt, Auteur ; Nancy A. Rigotti, Auteur ; Raymond S. Niaura, Auteur ; David H. Gonzales, Auteur Editeur : American College of Physicians Année de publication : 2001 Collection : Annals of internal medicine, ISSN 0003-4819 num. 135 Importance : p. 423-433 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude [TABAC] étude:recherche:recherche clinique:essai clinique randomisé [TABAC] prévention [TABAC] sevrage tabagique:efficacité du sevrage:rechute [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:placebo Index. décimale : TA 6.2.3 Approche pharmacologique Résumé : Essai clinique randomisé ayant pour but de déterminer l'efficacité du bupropion pour prévenir la rechute. En ligne : https://doi.org/10.7326/0003-4819-135-6-200109180-00011 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10392

Aucun avis, veuillez vous identifier pour ajouter le vôtre !

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers / Raymond S. Niaura (2008)

Public Titre : The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers : a randomized controlled trial Type de document : texte imprimé Auteurs : Raymond S. Niaura, Auteur ; J. Taylor Hays, Auteur ; Douglas E. Jorenby, Auteur Editeur : Abingdon [Angleterre] : Taylor & Francis Group Année de publication : 2008 Collection : Current medical research and opinion, ISSN 0300-7995 num. Vol 24, n. 7 Importance : p. 1931-1941 Présentation : graph., tab. Langues : Anglais (eng) Catégories : [TABAC] étude [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline Index. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Résumé : Abstract OBJECTIVE: To determine whether self-regulated flexible dosing with varenicline tartrate is safe and effective for smoking cessation. RESEARCH DESIGN AND METHODS: 320 healthy, motivated-to-quit smokers (> or =10 cigarettes/day) aged 18-65 years, entered a multicenter, randomized, double-blind, placebo-controlled study - conducted between December 26, 2001 and June 24, 2003 - with a 12-week treatment phase and 40-week, double-blind, non-treatment follow-up. Treatment consisted of varenicline or placebo in fixed doses (Week 1: titrated from 0.5 to 1.0 mg/day) followed by a self-regulated flexible schedule (Weeks 2-12: 0.5-2.0 mg/day). MAIN OUTCOME MEASURES: Primary outcomes included carbon monoxide-confirmed continuous abstinence rate (CAR) from smoking for Weeks 4 through 7, 9 through 12, and 9 through 52. Secondary outcomes included CAR from Weeks 9 through 24, 7-day point prevalence of abstinence, safety assessments, and measures of craving, withdrawal, and smoking reward. RESULTS: Superior CARs were observed in varenicline-treated (n = 157) versus placebo participants (n=155) for Weeks 4 through 7 (38.2 vs. 11.6%), 9 through 12 (40.1 vs. 11.6%), 9 through 24 (28.0 vs. 9.0%), and 9 through 52 (22.3 vs. 7.7%) (all p<0.001). Seven-day point prevalence was higher in varenicline-treated than placebo participants at Weeks 12 (46.5 vs. 14.2%; p<0.001), 24 (32.5 vs. 13.5%; p<0.001), and 52 (28.0 vs. 13.5%; p=0.001). Overall, medication compliance was high, although varenicline-treated, but not placebo, participants tended to taper down their dosage over time. Total treatment-emergent AEs were 77.1% (varenicline: 121/157) and 65.8% (placebo: 102/155). Few AEs led to treatment discontinuation (varenicline: 11/157, 7.0% and placebo: 7/155, 4.5%). Participants were primarily healthy Caucasians, so more research is necessary to determine how applicable these findings are to other populations. CONCLUSIONS: A self-regulated, flexible dosing regimen of varenicline is well tolerated, with superior effectiveness versus placebo for smoking cessation. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7940

Exemplaires (1)

Code-barres	Cote	Support	Localisation	Section	Disponibilité
TA 005481	TA 6.2.3.1.4 NIA E	Article/Périodique	Bibliothèque FARES	Tabac	Consultation sur place Exclu du prêt

Aucun avis, veuillez vous identifier pour ajouter le vôtre !